Corporate Information – Page 5 – Alligator Bioscience

2024-03-07

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activity Early promising signs of clinical activity in ...

2024-02-082024-02-14

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2024-02-082024-03-21

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-02-082024-02-14

Regulatory

Expected annual cash savings of SEK 20 million Restructuring follows successful conclusion of resource intensive OPTIMIZE-1 Phase 2 trial Fo ...

2024-01-292024-02-14

Regulatory

Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...

2024-01-16

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the United States Patent and Trademark Office (USPT ...

2023-11-09

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...

2023-11-06

Regulatory

The press release as of November 6, 2023 regarding the Nomination Committee appointed in respect of AGM 2024 incorrectly stated Hans-Peter O ...

2023-11-06

Regulatory

Lund, Sweden, November 6, 2023– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...